MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-08-2024
Emergent BioSolutions Operating Income 2011-2026 | EBS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Emergent BioSolutions
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -726 M | -170 M | 341 M | 438 M | 114 M | 89.8 M | 124 M | 106 M | 142 M | 89.2 M | 42.8 M | 30 M | 32.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 438 M | -726 M | 50.2 M |
Quarterly Operating Income Emergent BioSolutions
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -242 M | - | -45.3 M | - | 6.4 M | - | -34.7 M | 14.5 M | 95.4 M | 258 M | 61.3 M | 126 M | -11.6 M | 77.8 M | 70.7 M | -7 M | -27.4 M | - | 21.3 M | 66.8 M | -9.5 M | - | 47.8 M | 8.53 M | 14.9 M | - | 35.5 M | -2.04 M | 21.2 M | 49.9 M | 63.2 M | 21.5 M | -28.3 M | 44.6 M | 31 M | 7.86 M | -25.5 M | 23.3 M | 18.1 M | 14.7 M | -13.4 M | 24 M | 9.82 M | 8.65 M | -12.5 M | 46 M | 1.41 M | 20.2 M | -35.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 258 M | -242 M | 19 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.19 | 4.74 % | $ 128 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.35 | 3.08 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.51 | -0.21 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-34.4 M | $ 6.7 | 0.68 % | $ 416 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 49.11 | 0.22 % | $ 1.6 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.2 | -0.83 % | $ 21 M |  China |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.17 | -13.31 % | $ 5.05 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.73 | 2.98 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 7.18 | 3.24 % | $ 2.62 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.01 | 0.88 % | $ 56.4 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.74 | 4.82 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 4.71 | -9.17 % | $ 620 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 24.43 | -5.6 % | $ 1.13 B | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.88 | 5.11 % | $ 20.5 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 13.96 | 0.29 % | $ 1.92 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | $ 0.32 | -27.93 % | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.36 | -9.73 % | $ 131 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 9.18 | 1.21 % | $ 652 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.47 | -3.01 % | $ 223 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.63 | 0.27 % | $ 30.1 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.67 | 0.82 % | $ 4.55 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 9.85 | 9.08 % | $ 6.09 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.61 | -1.23 % | $ 16.8 M | USA |
 |
Zomedica Corp.
ZOM
|
-31.6 M | - | -0.21 % | $ 98 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.28 | 6.54 % | $ 308 M | USA |